Companies / Belgium
UCB Posts Robust Financial Results
August 2006 | Company Finance AlertMatching compatriot firm Solvay, Belgian drugmaker UCB has released strong financial results for the first half of 2006 in which revenues increased by 12% to EUR1.3bn (US$1.7bn). Net profit from continuing operations rose by 44% to EUR237mn (US$303mn), including a net capital gain of EUR57mn (US$73mn) on the sale of non-core businesses and brands, and after restructuring expenses.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
